Cell-Specific Genetic Mapping Links Neuronal and Immune Pathways to Neuropsychiatric Risk

Mapping the Cellular Architecture of Neuropsychiatric Risk

The clinical management of neuropsychiatric disorders remains challenged by a highly polygenic architecture, a genetic structure where thousands of small-effect variants collectively influence disease risk [1, 2, 3]. While genome-wide association studies have identified numerous risk loci, such as the 102 independent variants associated with major depression [1] and 102 risk genes identified in autism spectrum disorder [4], the specific cellular mechanisms driving pathology often remain elusive [5, 6]. Recent evidence suggests these conditions involve more than primary neuronal defects, specifically implicating neuroinflammation and dysregulation of the brain extracellular matrix, which is the scaffold of molecules providing structural and biochemical support to cells [7, 8]. Furthermore, the overlap between central nervous system symptoms and peripheral immune markers, including shared genetic pathways between blood cell indices and schizophrenia [9], suggests a systemic component to these traditionally brain-centered illnesses [2]. A new study [6] now integrates single-cell expression quantitative trait locus data (a method to identify genetic variants that influence the expression levels of genes in specific cell types) with large-scale genetic associations to map risk to specific cell types across six major disorders.

Identifying 345 Cell-Specific Risk Genes

To move beyond broad genetic associations that lack anatomical precision, the researchers integrated single-cell expression quantitative trait locus (sc-eQTL) data from both brain and blood tissues with existing genome-wide association studies. This approach allowed the team to pinpoint genetic variants that influence the expression levels of specific genes within individual cell types rather than across the entire tissue. The analysis focused on six major neuropsychiatric and neurodegenerative conditions: schizophrenia, Parkinson's disease, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder (ADHD), and autism spectrum disorder. By combining these high-resolution expression maps with large-scale clinical genetic data, the study sought to bridge the gap between inherited risk variants and their actual functional impact on cellular biology, providing a clearer picture of which cells are actually malfunctioning in a given patient. The researchers employed summary-data-based Mendelian randomization (SMR) across a diverse array of neuronal and immune cell types to identify putative causal genes. Summary-data-based Mendelian randomization is a statistical method that uses genetic variants as instrumental variables to test the causal effect of gene expression on a clinical trait, effectively mimicking a randomized controlled trial to reduce confounding factors. Through this rigorous analysis, the study identified 345 cell-type-specific risk genes associated with the six disorders. This cell-type-specific mapping uncovered etiological mechanisms that were previously obscured in bulk-tissue analyses, which typically average genetic signals across all cell types in a sample and can mask the distinct contributions of rarer cell populations like microglia or specific inhibitory neurons.

Divergent Roles for Neurons and Glia

The study's cell-specific resolution revealed that certain genes exert their influence across multiple clinical phenotypes through specific neuronal populations, suggesting a shared biological substrate for seemingly different diagnoses. For instance, FLOT1 was identified as a risk gene in both excitatory neurons and inhibitory neurons for schizophrenia, bipolar disorder, and major depressive disorder. This finding suggests that the protein flotillin 1, which is involved in vesicular trafficking and signal transduction at the synapse, may represent a common pathological link across these three major psychiatric conditions. By localizing this risk to both primary signaling neurons (excitatory) and the cells responsible for modulating those signals (inhibitory), the data provide a cellular context for the shared clinical features often observed in these disorders. Beyond traditional neuronal pathways, the researchers highlighted the critical role of glia, the non-neuronal support cells of the central nervous system. A key finding was that MAPT was identified as a risk gene in astrocytes for schizophrenia and Parkinson's disease. While MAPT (microtubule-associated protein tau) is traditionally associated with neurodegenerative proteinopathies, its specific expression in astrocytes (cells that maintain the blood-brain barrier and regulate the chemical environment of the brain) suggests that astrocyte dysfunction may contribute to the pathogenesis of both a primary psychotic disorder and a movement disorder. This localization underscores the importance of glial support mechanisms in maintaining neurological health and indicates that the genetic risk for these conditions is not confined to neurons alone. The integration of single-cell data also uncovered previously unrecognized associations within the brain's immune landscape. Specifically, APTX was identified as a novel risk gene association in microglia for schizophrenia. Microglia serve as the resident immune cells of the brain, responsible for synaptic pruning and inflammatory responses. The identification of APTX (aprataxin), a gene involved in DNA repair, within these immune cells suggests that impaired microglial function or an altered immune response may be a driver of schizophrenia risk. These findings collectively indicate that neuropsychiatric disorders arise from a complex interplay of neuronal dysfunction and immune system dysregulation, shifting the clinical focus toward a more integrated view of brain pathology that includes both the signaling architecture and the underlying immune and support infrastructure.

Shared Pathways and Tissue Specificity

The cross-disorder analyses conducted by the researchers identified shared biological pathways in synaptic function and immune regulation across the six conditions studied, reinforcing the idea that these disorders may exist on a biological continuum. By examining the overlap of genetic risk, the study found that the mechanisms governing how neurons communicate at the synapse and how the brain manages inflammatory responses are common denominators in the pathogenesis of schizophrenia, Parkinson's disease, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, and autism spectrum disorder. However, the researchers also noted that disease-specific and tissue-specific patterns were observed across the different disorders, indicating that while shared pathways exist, the clinical manifestation of each condition is likely driven by unique genetic signatures that operate within specific anatomical or cellular contexts. A critical finding of the study was that brain-derived risk genes exhibited significantly higher cell-type specificity than those identified in blood. This suggests that the genetic drivers of neuropsychiatric risk in the central nervous system are highly localized to specific cellular environments, such as particular neuronal subtypes or glial cells, whereas genetic effects measured in peripheral blood are more diffuse. For the practicing clinician, these findings suggest that neuropsychiatric disorders arise from a combination of neuronal dysfunction and immune system dysregulation, rather than a single pathological process. This integrated model of disease suggests that future therapeutic strategies may need to target both the signaling architecture of the synapse and the regulatory functions of the immune system to effectively manage these complex conditions, raising the prospect that future diagnostic tools could match patients to targeted interventions based on their neurobiological profile.

References

1. Howard DM, Adams MJ, Clarke T, et al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. Nature Neuroscience. 2019. doi:10.1038/s41593-018-0326-7

2. Zallar L, Dupont MB. Brain and Blood Biomarkers of Major Depressive Disorder: A Systematic Review.. JAMA psychiatry. 2026. doi:10.1001/jamapsychiatry.2025.4613

3. Nievergelt CM, Maihofer AX, Klengel T, et al. International meta-analysis of PTSD genome-wide association studies identifies sex- and ancestry-specific genetic risk loci. Nature Communications. 2019. doi:10.1038/s41467-019-12576-w

4. Satterstrom FK, Kosmicki JA, Wang J, et al. Large-Scale Exome Sequencing Study Implicates Both Developmental and Functional Changes in the Neurobiology of Autism. Cell. 2020. doi:10.1016/j.cell.2019.12.036

5. Wei H, Zhu Y, Wang T, Zhang X, Zhang K, Zhang Z. Genetic risk factors for autism-spectrum disorders: a systematic review based on systematic reviews and meta-analysis.. Journal of neural transmission (Vienna, Austria : 1996). 2021. doi:10.1007/s00702-021-02360-w

6. Wang X, Luo L, Chang S, Yang L. Cell-type-specific genetic architecture reveals neuronal and immune contributions to neuropsychiatric disorders.. Molecular psychiatry. 2026. doi:10.1038/s41380-026-03606-3

7. Zhang W, Xiao D, Mao Q, Xia H. Role of neuroinflammation in neurodegeneration development. Signal Transduction and Targeted Therapy. 2023. doi:10.1038/s41392-023-01486-5

8. Sadis H, Rike W, Peles D, et al. Brain extracellular matrix implications in multiple neurological disorders revealed through a meta-analysis of transcriptional changes.. Neurobiology of Disease. 2026. doi:10.1016/j.nbd.2026.107263

9. Astle WJ, Elding H, Jiang T, et al. The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease. Cell. 2016. doi:10.1016/j.cell.2016.10.042